Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity

被引：445

作者：

Ewer, MS

Lippman, SM

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA

[3] Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 13期

关键词：

D O I：

10.1200/JCO.2005.05.827

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2900 / 2902

页数：3

共 30 条

[1] The convergence of cancer prevention and therapy in early-phase clinical drug development [J].

Abbruzzese, JL ;

Lippman, SM .

CANCER CELL, 2004, 6 (04) :321-326

[2]

ALI MK, 1994, CANCER-AM CANCER SOC, V74, P182, DOI 10.1002/1097-0142(19940701)74:1<182::AID-CNCR2820740129>3.0.CO

[3]

2-2

[4]

BILLINGHAM ME, 1978, CANCER TREAT REP, V62, P865

[5] ErbB2 is essential in the prevention of dilated cardiomyopathy [J].

Crone, SA ;

Zhao, YY ;

Fan, L ;

Gu, YS ;

Minamisawa, S ;

Liu, Y ;

Peterson, KL ;

Chen, J ;

Kahn, R ;

Condorelli, G ;

Ross, J ;

Chien, KR ;

Lee, KF .

NATURE MEDICINE, 2002, 8 (05) :459-465

[6] Reversibility of trastuzumab-induced congestive heart failure in patients previously treated with anthracyclines [J].

Ewer, MS ;

Vooletich, MT ;

Woods, M ;

Durand, JB ;

Lenihan, DJ .

JOURNAL OF CARDIAC FAILURE, 2004, 10 (04) :S117-S117

[7]

Ewer MS, 1999, SEMIN ONCOL, V26, P96

[8]

EWER MS, 2004, P AN M AM SOC CLIN, V23, P148

[9]

EWER MS, SEMIN ONCOL, V31, P161

[10]

EWER MS, 2002, P AN M AM SOC CLIN, V21, pA123

← 1 2 3 →